US Stocks Movement | AstraZeneca (AZN.US) rises over 2% as Goldman Sachs is bullish, raising price target to $99
According to Jinse Finance APP, on Wednesday, AstraZeneca (AZN.US) rose more than 2%, closing at $81.99. Recently, Goldman Sachs released a research report stating that AstraZeneca announced positive results for Baxdrostat in the Phase III BaxHTN clinical trial at the 2025 European Society of Cardiology (ESC) annual meeting. Baxdrostat demonstrated strong efficacy in treating hypertension during the clinical trial and is expected to bring AstraZeneca sales opportunities worth several billions of dollars. Goldman Sachs has given AstraZeneca a "Buy" rating, with a 12-month target price of $99. This target price represents an upside of about 23% compared to the stock's closing price of $80.19 on Tuesday.
According to the information, Baxdrostat is a highly selective aldosterone synthase inhibitor (ASI) that targets one of the hormones responsible for increased blood pressure and elevated cardiovascular and renal risks. Currently, the drug is undergoing clinical trials worldwide, with more than 20,000 patients enrolled. The trials include monotherapy for hypertension and primary aldosteronism, combination therapy with dapagliflozin for chronic kidney disease and hypertension, as well as prevention of heart failure in hypertensive patients. It is reported that Baxdrostat is expected to be approved in the US and Europe in the first half of 2026, becoming the world's first marketed aldosterone synthase inhibitor (ASI) antihypertensive drug.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After Japanese Official’s Statement, Besant Steps In: “Merit of Strong Yen” Already Discussed with Japan’s Finance Minister
Besant stated that he had a "productive call" with Japanese Finance Minister Mitsuru Sakazuki on Friday, during which they discussed the desirability of a strong yen that reflects Japan's robust economic fundamentals and emphasized the importance of maintaining close communication regarding the foreign exchange market. Sakazuki earlier revealed that during a meeting this week between Trump and Sanae Takaichi, both mentioned the weakening yen. Takaichi said that the undervaluation of the yen is "problematic." Institutions believe that the risk of intervention may "cap" the yen's decline.
Litecoin jumps 30% from its lows: can an $80 breakout send LTC to $135?
Top crypto price predictions: Quant, Chainlink, Ondo Coin
NEAR price rally meets Bitwise ETF listing, is $5 next?
Crypto prices
More
